Eisai Co. Ltd.

In News

Brush for Freedom - Eisai

Eisai - Mar 16, 2026

EISAI TO BEGIN ENROLLING PHASE 2 STUDY IN PATIENTS WITH NARCOLEPSY - PR Newswire

PR Newswire - Mar 26, 2026

Don't Race Out To Buy Eisai Co., Ltd. (TSE:4523) Just Because It's Going Ex-Dividend - simplywall.st

simplywall.st - Mar 26, 2026

We’re teaming up with Eisai to help fight cancer - Merck.com

Merck.com - Mar 12, 2026

Eisai strikes Japan licensing deal with Shanghai Henlius Biotech - reuters.com

reuters.com - Feb 05, 2026

Eisai Co Ltd And Biogen Inc Announce Real-World Long-Term Treatment Persistence With Leqembi - marketscreener.com

marketscreener.com - Mar 20, 2026

Eisai begins enrollment for narcolepsy drug E2086 phase 2 study - Investing.com

Investing.com - Mar 26, 2026

Eisai to Launch “Pariet® S,” the First Proton Pump Inhibitor RX-to-OTC in Japan - Eisai

Eisai - Jun 02, 2025

Eisai Maintains Commitment to People Living with Early Alzheimer's Disease Despite CDA-AMC Draft Recommendation: Patients Deserve Access to Effective Treatment - biospace.com

biospace.com - Feb 19, 2026

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China - Biogen

Biogen - Feb 08, 2026

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency – Company Announcement - Financial Times

Financial Times - Mar 26, 2026

Eisai Co., Ltd. (TSE:4523) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year - simplywall.st

simplywall.st - Feb 11, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment